Jaguar Health Inc (NASDAQ:JAGX) has received an average broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company.
Brokers have set a twelve-month consensus price target of $69.93 for the company and are predicting that the company will post ($9.09) earnings per share for the current quarter, according to Zacks. Zacks has also given Jaguar Health an industry rank of 76 out of 256 based on the ratings given to its competitors.
Several equities research analysts have recently weighed in on the stock. ValuEngine cut shares of Jaguar Health from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. HC Wainwright reissued a “buy” rating on shares of Jaguar Health in a research note on Monday, April 15th.
Shares of JAGX traded down $0.84 during trading hours on Friday, hitting $6.94. 392,428 shares of the stock were exchanged, compared to its average volume of 542,946. Jaguar Health has a fifty-two week low of $6.80 and a fifty-two week high of $175.00. The company has a quick ratio of 0.18, a current ratio of 0.30 and a debt-to-equity ratio of 0.02. The stock has a market cap of $10.43 million, a PE ratio of -0.04 and a beta of 1.26.
Jaguar Health Company Profile
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Featured Story: What does an equal weight rating mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.